Table 1.
Clinical characteristics of the patients.
| Initial treatment | Salvage BT | |
|---|---|---|
| Median age (range), years | 79 (62−89) | 80 (75−89) |
| Median PSA at diagnosis | 8.15 ng/mL (6.85−13.95) | <10 ng/mL |
| EBRT | 3.37 (3.06−3.85) | |
| LDR-BT | 3.74 (2.86−5.74) | |
| Clinical stage | ||
| T1c | 11 | |
| T2a | 7 | 8 |
| T2b | 5 | 16 |
| T2c | 3 | 7 |
| T3a | 2 | |
| T3b | 1 | |
| Unknown | 1 | |
| Gleason | ||
| ≤6 | 13 | 4 |
| 7 | 15 | 19 |
| >7 | 1 | 4 |
| Unknown | 1 | 3 |
| D´Amico risk group | ||
| Low risk | 13 | |
| Intermediate risk | 12 | |
| High risk | 6 | |
| Treatment received | ||
| EBRT | 14 | |
| <72 Gy | 8 | |
| >72 Gy | 6 | |
| LDR-BT | 16 | 30 |
| 120 Gy | 21 | |
| 125Gy | 1 | |
| 130Gy | 8 | |
| 145 Gy | 14 | |
| 160Gy | 2 | |
| PSA nadir | ||
| EBRT | 0.27 ng/mL (0−1.8) | 0.14 ng/mL (0.06−0.75) |
| LDR-BT | 0.4 ng/mL (0.1−1.2) | 0.45 ng/mL (0.01−1.31) |
| ADT | 19/30 | 6/30 |
ADT indicates androgen-deprivation therapy; PSA, prostate-specific antigen; EBRT, external beam radiation therapy; BT, brachytherapy.